Ribavirin monitoring in chronic hepatitis C therapy: Anaemia versus efficacy

Antiviral Therapy

Volumn 15, Issue 5, 2010, Pages 687-695

  Brochot, Etienne ^a,b   Castelain, Sandrine ^a,b   Duverlie, Gilles ^a,b   Capron, Dominique ^a,b   Nguyen Khac, Eric ^a   François, Catherine ^a  

^a AMIENS UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE PICARDIE JULES VERNE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; ALPHA2B INTERFERON; RIBAVIRIN;

AREA UNDER THE CURVE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MONITORING; DRUG WITHDRAWAL; GENOTYPE; HEMODIALYSIS PATIENT; HEMOLYTIC ANEMIA; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; NAUSEA; OBESITY; PATIENT MONITORING; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; REVIEW; RISK FACTOR; SKIN DISEASE; STEADY STATE;

ANEMIA, HEMOLYTIC; ANTIVIRAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; RIBAVIRIN; TREATMENT OUTCOME;

EID: 77957378084     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1609     Document Type: Review

References (67)

1. Alter HJ. HCV natural history: the retrospective and prospective in perspective. J Hepatol 2005; 43:550-552.
2. Jacobson IM, Brown RS, Jr., McCone J, et al. Impact of weight-based ribavirin with peginterferon alfa-2b in African Americans with hepatitis C virus genotype 1. Hepatology 2007; 46:982-990. (Pubitemid 350144762)
3. Lee SS, Heathcote EJ, Reddy KR, et al. Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD). J Hepatol 2002; 37:500-506.
4. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358:958-965. (Pubitemid 32913521)
5. McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123:1061-1069.
6. Back D, Gibbons S, Khoo S. An update on therapeutic drug monitoring for antiretroviral drugs. Ther Drug Monit 2006; 28:468-473.
7. Snoeck E, Wade JR, Duff F, Lamb M, Jorga K. Predicting sustained virological response and anaemia in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) plus ribavirin. Br J Clin Pharmacol 2006; 62:699-709.
8. Arase Y, Ikeda K, Tsubota A, et al. Significance of serum ribavirin concentration in combination therapy of interferon and ribavirin for chronic hepatitis C. Intervirology 2005; 48:138-144. (Pubitemid 41201504)
9. Jacobson IM, Brown RS, Jr., Freilich B, et al. Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial. Hepatology 2007; 46:971-981.
10. Crotty S, Maag D, Arnold JJ, et al. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat Med 2000; 6:1375-1379. (Pubitemid 32001022)
11. Crotty S, Cameron CE, Andino R. RNA virus error catastrophe: direct molecular test by using ribavirin. Proc Natl Acad Sci U S A 2001; 98:6895-6900. (Pubitemid 32538313)
12. Brochot E, Duverlie G, Castelain S, et al. Effect of ribavirin on the hepatitis C virus (JFH-1) and its correlation with interferon sensitivity. Antivir Ther 2007; 12:805-813. (Pubitemid 47235495)
13. Leyssen P, Balzarini J, De Clercq E, Neyts J. The predominant mechanism by which ribavirin exerts its antiviral activity in vitro against flaviviruses and paramyxoviruses is mediated by inhibition of IMP dehydrogenase. J Virol 2005; 79:1943-1947.
14. Hultgren C, Milich DR, Weiland O, Sällberg M. The antiviral compound ribavirin modulates the T helper (Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune responses. J Gen Virol 1998; 79:2381-2391. (Pubitemid 28464295)
15. Maag D, Castro C, Hong Z, Cameron CE. Hepatitis C virus RNA-dependent RNA polymerase (NS5B) as a mediator of the antiviral activity of ribavirin. J Biol Chem 2001; 276:46094-46098.
16. Feld JJ, Nanda S, Huang Y, et al. Hepatic gene expression during treatment with peginterferon and ribavirin: identifying molecular pathways for treatment response. Hepatology 2007; 46:1548-1563.
17. Kamar N, Chatelut E, Manolis E, Lafont T, Izopet J, Rostaing L. Ribavirin pharmacokinetics in renal and liver transplant patients: evidence that it depends on renal function. Am J Kidney Dis 2004; 43:140-146. (Pubitemid 38049445)
18. Laskin OL, Longstreth JA, Hart CC, et al. Ribavirin disposition in high-risk patients for acquired immunodeficiency syndrome. Clin Pharmacol Ther 1987; 41:546-555. (Pubitemid 17074331)
19. Homma M, Matsuzaki Y, Inoue Y, et al. Marked elevation of erythrocyte ribavirin levels in interferon and ribavirin-induced anemia. Clin Gastroenterol Hepatol 2004; 2:337-339. (Pubitemid 38447199)
20. De Franceschi L, Fattovich G, Turrini F, et al. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. Hepatology 2000; 31:997-1004. (Pubitemid 30169949)
21. Page T, Connor JD. The metabolism of ribavirin in erythrocytes and nucleated cells. Int J Biochem 1990; 22:379-383.
22. Inoue Y, Homma M, Matsuzaki Y, et al. Erythrocyte ribavirin concentration for assessing hemoglobin reduction in interferon and ribavirin combination therapy. Hepatol Res 2006; 34:23-27.
23. Nomura H, Tanimoto H, Kajiwara E, et al. Factors contributing to ribavirin-induced anemia. J Gastroenterol Hepatol 2004; 19:1312-1317.
24. Bodenheimer HC, Jr., Lindsay KL, Davis GL, Lewis JH, Thung SN, Seeff LB. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Hepatology 1997; 26:473-477.
25. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998; 352:1426-1432.
26. Hung C-H, Lee C-M, Lu S-N, et al. Anemia associated with antiviral therapy in chronic hepatitis C: incidence, risk factors, and impact on treatment response. Liver Int 2006; 26:1079-1086.
27. Saito H, Tada S, Ebinuma H, et al. Role of erythrocytes as a reservoir for ribavirin and relationship with adverse reactions in the early phase of interferon combination therapy for chronic hepatitis C virus infections. J Clin Microbiol 2006; 44:3562-3568. (Pubitemid 46768817)
28. Van Vlierberghe H, Delanghe JR, De Vos M, Leroux-Roel G, BASL Steering Committee. Factors influencing ribavirin-induced hemolysis. J Hepatol 2001; 34:911-916.
29. Krishnan SM, Dixit NM. Estimation of red blood cell lifespan from alveolar carbon monoxide measurements. Transl Res 2009; 154:15-17.
30. Virtue MA, Furne JK, Ho SB, Levitt MD. Use of alveolar carbon monoxide to measure the effect of ribavirin on red blood cell survival. Am J Hematol 2004; 76:107-113.
31. Moore RD. Human immunodeficiency virus infection, anemia, and survival. Clin Infect Dis 1999; 29:44-49. (Pubitemid 29336799)
32. Alvarez D, Dieterich DT, Brau N, Moorehead L, Ball L, Sulkowski MS. Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons. J Viral Hepat 2006; 13:683-689. (Pubitemid 44401197)
33. Lafeuillade A, Hittinger G, Chadapaud S. Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection. Lancet 2001; 357:280-281. (Pubitemid 32120863)
34. Vispo E, Barreiro P, Pineda JA, et al. Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir. Antivir Ther 2008; 13:429-437. (Pubitemid 352016736)
35. Oze T, Hiramatsu N, Kurashige N, et al. Early decline of hemoglobin correlates with progression of ribavirin-induced hemolytic anemia during interferon plus ribavirin combination therapy in patients with chronic hepatitis C. J Gastroenterol 2006; 41:862-872. (Pubitemid 44594227)
36. Reau N, Hadziyannis SJ, Messinger D, Fried MW, Jensen DM. Early predictors of anemia in patients with hepatitis C genotype 1 treated with peginterferon alfa-2a (40KD) plus ribavirin. Am J Gastroenterol 2008; 103:1981-1988.
37. Grattagliano I, Russmann S, Palmieri VO, et al. Low membrane protein sulfhydrils but not G6PD deficiency predict ribavirin-induced hemolysis in hepatitis C. Hepatology 2004; 39:1248-1255.
38. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-982.
39. Hadziyannis SJ, Sette H, Jr., Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140:346-355.
40. Dalgard O, Mangia A. Short treatment to patients with genotype 2 or 3. Hepatology 2008; 48:694.
41. Zeuzem S, Hultcrantz R, Bourliere M, et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004; 40:993-999.
42. François C, Castelain S, Duverlie G, Capron D, Nguyen-Khac E. Optimizing the treatment of chronic viral hepatitis C. Expert Rev Gastroenterol Hepatol 2009; 3:607-613.
43. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351:438-450.
44. Núñez M, Miralles C, Berdún MA, et al. Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial. AIDS Res Hum Retroviruses 2007; 23:972-982.
45. Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004; 292:2839-2848. (Pubitemid 39628231)
46. Bruchfeld A, Lindahl K, Schvarcz R, Ståhle L. Dosage of ribavirin in patients with hepatitis C should be based on renal function: a population pharmacokinetic analysis. Ther Drug Monit 2002; 24:701-708. (Pubitemid 35379522)
47. Lindahl K, Stahle L, Bruchfeld A, Schvarcz R. High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C. Hepatology 2005; 41:275-279.
48. Arase Y, Ikeda K, Suzuki F, et al. Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and ribavirin for chronic hepatitis C. J Gastroenterol 2004; 39:1090-1094. (Pubitemid 39618793)
49. Maeda Y, Kiribayashi Y, Moriya T, et al. Dosage adjustment of ribavirin based on renal function in Japanese patients with chronic hepatitis C. Ther Drug Monit 2004; 26:9-15.
50. Maynard M, Pradat P, Gagnieu MC, Souvignet C, Trepo C. Prediction of sustained virological response by ribavirin plasma concentration at week 4 of therapy in hepatitis C virus genotype 1 patients. Antivir Ther 2008; 13:607-611.
51. Loustaud-Ratti V, Alain S, Rousseau A, et al. Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C. Hepatology 2008; 47:1453-1461. (Pubitemid 351702729)
52. Tsubota A, Hirose Y, Izumi N, Kumada H. Pharmacokinetics of ribavirin in combined interferon-alpha 2b and ribavirin therapy for chronic hepatitis C virus infection. Br J Clin Pharmacol 2003; 55:360-367. (Pubitemid 36535366)
53. Aguilar Marucco D, Gonzalez de Requena D, Bonora S, et al. The use of trough ribavirin concentration to predict sustained virological response and haematological toxicity in HIV/HCV-co-infected patients treated with ribavirin and pegylated interferon. J Antimicrob Chemother 2008; 61:919-924. (Pubitemid 351426079)
54. Rendón AL, Núñez M, Romero M, et al. Early monitoring of ribavirin plasma concentrations may predict anemia and early virologic response in HIV/hepatitis C virusco-infected patients. J Acquir Immune Defic Syndr 2005; 39:401-405. (Pubitemid 41003783)
55. Dahari H, Markatou M, Zeremski M, et al. Early ribavirin pharmacokinetics, HCV RNA and alanine aminotransferase kinetics in HIV/HCV co-infected patients during treatment with pegylated interferon and ribavirin. J Hepatol 2007; 47:23-30. (Pubitemid 46817685)
56. Nicot F, Legrand-Abravanel F, Lafont T, et al. Serum concentrations of ribavirin and pegylated interferon and viral responses in patients infected with HIV and HCV. J Med Virol 2008; 80:1523-1529.
57. Lindahl K, Schvarcz R, Bruchfeld A, Ståhle L. Evidence that plasma concentration rather than dose per kilogram body weight predicts ribavirin-induced anaemia. J Viral Hepat 2004; 11:84-87.
58. McHutchison JG, Manns MP, Longo DL. Definition and management of anemia in patients infected with hepatitis C virus. Liver Int 2006; 26:389-398.
59. Shiffman ML, Di Bisceglie AM, Lindsay KL, et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004; 126:1015-1023.
60. Hino K, Murakami Y, Nagai A, et al. Alpha-tocopherol and ascorbic acid attenuates the ribavirin induced decrease of eicosapentaenoic acid in erythrocyte membrane in chronic hepatitis C patients. J Gastroenterol Hepatol 2006; 21:1269-1275. (Pubitemid 44034339)
61. Takaki S, Kawakami Y, Imamura M, et al. Eicosapentaenoic acid could permit maintenance of the original ribavirin dose in chronic hepatitis C virus patients during the first 12 weeks of combination therapy with pegylated interferon-alpha and ribavirin. A prospective randomized controlled trial. Intervirology 2007; 50:439-446.
62. Morisco F, Vitaglione P, Carbone A, et al. Tomato-based functional food as interferon adjuvant in HCV eradication therapy. J Clin Gastroenterol 2004; 38 Suppl 6:S118-S120.
63. Sherman M, Cohen L, Cooper MA, et al. Clinical recommendations for the use of recombinant human erythropoietin in patients with hepatitis C virus being treated with ribavirin. Can J Gastroenterol 2006; 20:479-485. (Pubitemid 44227466)
64. McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009; 360:1827-1838.
65. Hezode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009; 360:1839-1850.
66. Pockros PJ, Nelson D, Godofsky E, et al. R1626 plus peginterferon Alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin. Hepatology 2008; 48:385-397.
67. Benhamou Y, Afdhal NH, Nelson DR, et al. A phase III study of the safety and efficacy of viramidine versus ribavirin in treatment-naive patients with chronic hepatitis C: ViSER1 results. Hepatology 2009; 50:717-726.